Dr. Tsiporah B. Shore, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 82
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 214077 -
Hematology (Internal Medicine) Physician
NY license 214077 -
Internal Medicine Physician
NY license 214077
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Weill Medical College of Cornell (2,051 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 82
- Services billed
- 693
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 318 | 41 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 92 | 21 |
| Established patient office or other outpatient visit, 30-39 minutes | 86 | 44 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Valacyclovir (valacyclovir hcl) Other prescribers in New York, NY | 29 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in New York, NY | 27 |
| Pantoprazole Sodium Other prescribers in New York, NY | 14 |
| Mirtazapine Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $21.05 in total to this clinician.
| Iovance Biotherapeutics, Inc. | $21.05 |
|---|
| Food and Beverage | $21.05 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $31,984 in research payments for these studies, mostly to the institutions running them.
- AGAVE-201, a phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab at 3 different doses in patients with recurrent or refractory active chronic graft versus…
Syndax Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.